Citations

Clear

58 citation(s) found for "Davis, Dawn M R".

Trends in utilization of non‐first‐line topical acne medications among children, adolescents, and adults in the United States, 2012‐2016
Afarideh, Mohsen , Baisi, Katinna E. Rodriguez , Davis, Dawn Marie R. , Hand, Jennifer L. , Tollefson, Megha M. , Rodriguez Baisi, Katinna , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | October 1, 2021 | Volume: 38 | Issue: 5 | Pages: 1066-1073

10.1111/pde.14733 | PMID 34595751 Get It

AbstractBackground/ObjectiveCurrent knowledge about usage of effective, but non‐first‐line topical acne medications in the United States is limited. We aimed to investigate utilization patterns and temporal trends for such acne medications in the US ambulatory care.MethodsPediatric (≤18 years old) and adult (>18 years old) data from the 2012 to 2016 (inclusive) cycles of the US National Ambulatory Medical Care Survey were extracted. Utilization patterns of six non‐first‐line topical acne medications (ie, azelaic acid, salicylic acid, glycolic acid, sulfur, resorcinol, and zinc) were compared and followed over time.ResultsData from 218 410 US office–based sampled visits during 2012‐2016 were included in the analysis. Across all acne visits (n = 1542), salicylic acid (1.58%), azelaic acid (1.22%), and glycolic acid (0.52%) were the most frequently used agents, while zinc and resorcinol were not used. Sulfur (0.52%) and salicylic acid (0.33%) were the only medications used in preadolescents, and none of these medications were used in the neonatal or infantile group. Temporal trends for using at least one of these medications were insignificant among both pediatric and adult age groups (P = .825 and .136, respectively).ConclusionsSalicylic acid and azelaic acid are the most frequently used of the studied second‐line medications to treat acne, although the use of these and the other non‐first‐line topical medications overall is uncommon, especially among younger groups of US pediatric patients.
Skin concerns in patients with trisomy 21 (Down syndrome): A Mayo Clinic 22‐year retrospective review
Wentworth, Ashley B., Hand, Jennifer L. , Davis, Dawn Marie R. , Tollefson, Megha M. , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | August 19, 2021 | Volume: 38 | Issue: S2 | Pages: 73-78

10.1111/pde.14764 | PMID 34409638 Get It

AbstractBackground/ObjectivesTrisomy 21 has known associated clinical phenotypes, including skin and soft tissue concerns. However, the overall prevalence and types of findings are largely unclear.MethodsA retrospective review of children with trisomy 21 and one or more dermatologic diagnoses, seen from 1/1/1994 to 7/1/2016, was performed to record dermatologic diagnoses. If one or more diagnoses were confirmed, further data were collected, including demographics, medical specialty, referrals to dermatology, treatment, complications, and follow‐up.ResultsOne hundred and seventy‐four patients with a diagnosis of trisomy 21 aged 18 years or younger were confirmed to have one or more dermatologic diagnoses. In a total of 479 dermatologic diagnoses, superficial mycoses (12%), skin and soft tissue infections (10%), dermatitis (8%), and folliculitis (8%) were most common. Diagnoses were most commonly made as an outpatient (91%) and by general pediatrics (45%) or dermatology (25%). A significant difference (P < .05) in the frequency of various diagnoses made by different specialties was observed. A significant difference (P < .05) in the treatments recommended by different specialties was also observed. Referrals to dermatology were infrequent (6%). However, a frequent change in diagnosis (61%) or treatment (68%) for patients referred to dermatology was observed.ConclusionsChildren with trisomy 21 are most commonly diagnosed with superficial mycoses, skin and soft tissue infections, dermatitis, and folliculitis. The majority of diagnoses were made by general pediatricians and although dermatology referral was rarely necessary, consultations often resulted in change of diagnosis and/or treatment, supporting consideration of early and frequent dermatology referral.
Autoimmune progesterone dermatitis in the adolescent population
Aghazadeh, Nessa , Chattha, Asma , Hartz, Martha F., Davis, Dawn Marie R. , Chattha, Asma J, Davis, Dawn M R , Aghazadeh Mohandesi, Nessa

Mayo Clinic

Pediatric Dermatology | December 27, 2020 | Volume: 38 | Issue: 2 | Pages: 380-384

10.1111/pde.14423 | PMID 33368681 Get It

AbstractBackground/ObjectiveAutoimmune progesterone dermatitis (APD) is a rare autoimmune hypersensitivity reaction that occurs cyclically at the peak of endogenous progesterone production during the menstrual cycle in women. No study characterizing APD in the adolescent population is found; it appears likely to be underdiagnosed and undertreated.MethodsA retrospective, single‐center, review of all adolescent and pediatric patients (<20 years old at onset) with documented diagnosis of APD.ResultsSeventeen adolescent APD patients were included (mean age at diagnosis: 14.4 ± 2 years, mean interval of 13.6 ± 11.1 months between symptom onset and diagnosis). Twelve patients presented with urticaria, two with fixed drug eruption. Erythema multiforme, eczema, and recurrent aphthous stomatitis were present in one patient each. Exposure to exogenous progestin was present in two patients prior to disease onset. Progesterone skin test was performed in six patients with positive results in two. Fourteen patients received antihistamines and/or a topical corticosteroid. Combined oral contraceptives (COCs) were given to eleven patients, in seven via continuous daily dosing. Gonadotropin‐releasing hormone agonist (GnRHa) was used in five, progesterone desensitization in four, omalizumab in two, and danazol in one patient.ConclusionsAdolescent APD is associated with a significant delay in diagnosis. The most common manifestation is urticaria. Exogenous exposure to progestins is uncommon in adolescent APD. Continuous COC, GnRHa, and progesterone desensitization have been used to control symptoms. Large, multicenter studies are required to better define, diagnose, and treat this under recognized condition among adolescent patients.
The anatomic distribution of isolated and syndrome‐associated port‐wine stain
Elias, Anna , Hand, Jennifer L. , Tollefson, Megha M. , Davis, Dawn Marie R. , Elias, Anna J , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | November 10, 2020 | Volume: 38 | Issue: 1 | Pages: 77-82

10.1111/pde.14392 | PMID 33170527 Get It

AbstractBackground/ObjectivesTo determine the role of sex in port‐wine stain (PWS) distribution and describe the epidemiologic and anatomic differences between syndrome‐associated and non‐syndrome‐associated PWS using modern criteria.MethodsA retrospective review of PWS patients aged 18 years and younger from 1995 to 2018 seen in the Department of Dermatology at an academic tertiary referral center. Cases were reviewed for sex, anatomic location, and presence of associated syndrome. 4,527 records were reviewed on the basis of ICD billing codes for congenital vascular malformations, with 516 meeting inclusion criteria.Results516 patients were included in the analysis: 234 (45.4%) men and 282 (54.6%) women. A female preponderance of Sturge‐Weber syndrome (18 of 23, 78%, P = .03) and a trend toward more female‐isolated PWS (149 of 269, 55%, P = .72) were found. No lateral predominance observed for isolated PWS was found: 112(41.6%) limited left‐side lesions and 113(42%) limited right‐side lesions (P = .41). A trend toward Klippel‐Trenaunay syndrome (KTS)‐associated PWS occurring more commonly isolated to the left side (76 (45.5%) vs 59 (35.12%) P = .29) was found. Nine percent of SWS patients had a PWS on the body. Five percent of KTS patients had a facial PWS. The lower limb was the most common location overall of body PWS with 33.8% of isolated PWS and 81.5% of KTS patients having a lower limb lesion.ConclusionsFemale children were more likely to be diagnosed with SWS, and a trend toward more isolated PWS in women was found. No lateral predominance of isolated PWS was found, but KTS‐associated PWS was more common on the left. A considerable proportion of lesions do not appear in anatomic locations traditionally considered typical in the setting of associated syndromes, which underscores the importance of conducting a complete physical examination and adhering to diagnostic criteria for those syndromes.
Hair Loss
Imhof, Reese L. , Tollefson, Megha M. , Davis, Dawn Marie R. , Imhof, Reese L

Mayo Clinic

Pediatrics In Review | November 2, 2020 | Volume: 41 | Issue: 11 | Pages: 570-584

10.1542/pir.2019-0009 | PMID 33139410 Get It

Use of spironolactone to treat acne in adolescent females
Roberts, Erin , Nowsheen, Somaira , Davis, Dawn Marie R. , Hand, Jennifer L. , Tollefson, Megha M. , Wetter, David A. , Roberts, Erin E, Davis, Dawn M R , Wetter, D A

Mayo Clinic

Pediatric Dermatology | October 3, 2020 | Volume: 38 | Issue: 1 | Pages: 72-76

10.1111/pde.14391 | PMID 33009838 Get It

AbstractBackground/objectivesStudies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we sought to examine spironolactone's role in treating this patient population.MethodsA retrospective review was performed to determine the efficacy of spironolactone treatment in adolescent females seen at Mayo Clinic in Rochester, Minnesota, from 2007 to 2017.ResultsIn a cohort of 80 pediatric patients with a median age of 19 years (range, 14‐20 years), 64 patients (80%) experienced improvement of acne on treatment with spironolactone (median dose, 100 mg daily) with a favorable side effect profile. Approximately a quarter of patients (22.5%) had a complete response; more than half (58.8%) had a complete response or a partial response greater than 50%. Initial and maximal responses were observed at a median of 3 months and 5 months, respectively. Patients received treatment with spironolactone for a median duration of 7 months (range, 3‐45 months) with limited side effects.ConclusionsSpironolactone demonstrated efficacy in treating acne in adolescent females and is a safe long‐term alternative to systemic antibiotics in these patients.
Oral erosions associated with surreptitious marijuana vaping in an adolescent boy
Ali, Nora S., Billings, Marcie, Tollefson, Megha M. , Davis, Dawn Marie R. , Hand, Jennifer L. , Billings, Marcie L, Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | January 22, 2020 | Volume: 37 | Issue: 2 | Pages: 347-349

10.1111/pde.14101 | PMID 31967343 Get It

AbstractA 15‐year‐old boy presented with painful ulcerations affecting the oral mucosa that were eventually attributed to marijuana vaping. In this case report, we highlight cannabis vaping as a potential cause of oral erosions due to injury and chronic inflammation of the oral mucosa.
Vision, mission, and values: From concept to execution at Mayo Clinic
Pruthi, Sandhya , Hucke, Dawn L, Ripple, Francesca B, Tatzel, Barbara S, Dilling, James A., Santrach, Paula J., Bolton, Jeffrey W., Noseworthy, John H., Davis, Dawn Marie R.

Mayo Clinic

Patient Experience Journal | June 27, 2019 | Volume: 2 | Issue: 2 | Pages: 168-173

10.35680/2372-0247.1082 Get It

Mayo Clinic displays steadfast commitment to patient care, referral relations, and health care quality through institutional examples of unique, value-add endeavors that are under way with the Mayo Clinic Patient Experience Subcommittee and the Referring Physician Office. In this article, we share the Mayo Model of Care and patient stories that embody the 8 Mayo Clinic values of respect, compassion, integrity, healing, teamwork, excellence, innovation, and stewardship. The Mayo founders imparted to their staff the passion for patient care by encouraging a fair and just culture for its employees. This culture allows the creation, maintenance, and improvement of clinical care, research studies, and educational curricula, which in turn propagate the mission–“To inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education, and research.”
Temporal trends in prenatal risk factors for the development of infantile hemangiomas
Schoch, Jennifer J. , Hunjan, Manrup , Anderson, Katelyn , Lohse, Christine M. , Hand, Jennifer L. , Tollefson, Megha M. , Hunjan, Manrup K , Anderson, Katelyn R, Davis, Dawn Marie R.

Mayo Clinic

Pediatric Dermatology | September 6, 2018 | Volume: 35 | Issue: 6 | Pages: 787-791

10.1111/pde.13659 | PMID 30187967 Get It

AbstractBackground/ObjectivesSpecific maternal risk factors have recently been identified in the development of infantile hemangiomas (IH), including gestational diabetes (GDM), maternal antihypertensive medication use or gestational hypertension (GHTN), maternal progesterone use, and artificial reproductive technologies (ART). We sought to explore the change in incidence of these risk factors over time and determine their association with the increased incidence of hemangiomas over 35 years, as previously reported.MethodsThe charts of 869 mother and infant pairs (infants previously diagnosed with IH between January 1, 1976, and December 31, 2010) were reviewed for prenatal complications. Rates of the prenatal complications over the 35‐year period in birth mothers of infants diagnosed with IH were determined and evaluated by year of diagnosis (1976‐1990, 1991‐2000, and 2001‐2010).ResultsOver the 35‐year period in which the incidence of IH was previously examined, maternal age at delivery, prepregnancy body mass index (BMI), use of ART, maternal progesterone use, placental abnormalities, and GDM also increased.ConclusionsGDM, ART, and maternal progesterone use increased over the past 35 years, mirroring the previously reported trend of increasing incidence of IH. Maternal age and BMI also increased in mothers of infants with IH. Further exploration of this association may direct future research in the pathogenesis of infantile hemangiomas.